“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.
Upon availability of new funding, Kinarus plans to start a Phase II study in wet AMD, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions, and in IPF. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.
Analyst - Healthcare
Dr. Alexander Bausch
CEO
Subhasis Roy
CFO
Forecast net debt (CHFm)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (29.3) | (10.2) | (84.6) |
| Relative | (26.5) | (9.7) | (82.7) |
| 52 week high/low | CHF0.1/CHF0.0 |
Kinarus Therapeutics is advancing KIN001, a patented orally dosed combination of p38 mitogen-activated protein kinase inhibitor pamapimod and pioglitazone. Preclinical data suggest this combination may have anti-inflammatory and anti-fibrotic activity, as well as antiviral properties against COVID-19. KIN001 is under development for the treatment of wet age-related macular degeneration (wet AMD), its lead indication, as well as idiopathic pulmonary fibrosis (IPF) and COVID-19. Wet AMD is a leading cause of vision loss in older adults and there are no oral drugs approved to treat the condition, signalling a potentially significant unmet need.
| Y/E Dec | Revenue (CHFm) | EBITDA (CHFm) | PBT (CHFm) | EPS (fd) (CHFc) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (1.5) | (1.5) | (31.17) | N/A | N/A |
| 2021A | 0.0 | (5.1) | (4.9) | (0.41) | N/A | N/A |
| 2022E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
